Annals of Allergy, Asthma, and Immunology: “Factors contributing to underuse of epinephrine autoinjectors in pediatric patients with food allergy.”
Tonya Winders, CEO and president, Allergy & Asthma Network.
Allergy: “A majority of parents of children with peanut allergy fear using the epinephrine auto-injector.”
The Journal of Allergy and Clinical Immunology: In Practice: “Community Use of Epinephrine for the Treatment of Anaphylaxis: A Review and Meta-Analysis.” “Fatal Anaphylaxis: Mortality Rate and Risk Factors.”
Journal of Asthma and Allergy: “Underuse of epinephrine for the treatment of anaphylaxis: missed opportunities.”
AAAAI: “Biphasic Anaphylaxis: Integrating Best Value Care with Patient Safety,” “Moving Away from Routine Emergency Department Evaluation After Treatment of Anaphylaxis – A Retrospective Review of Epinephrine Usage Among High-Risk Peanut-Allergic Children,” “Pharmacokinetics and Pharmacodynamics of Neffy (1 mg) compared to EpiPen (0.3 mg) and Manual IM injection (0.3 mg) – an Integrated Analysis,” “Subanalysis of an Open-Label, Crossover Study to Assess the Relative Bioavailability of Self-administered Nasal Epinephrine Compared to Administration by Trained Health Personnel in Healthy Adult Subjects,” “A Phase 1, Randomized Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single Ascending Doses of Epinephrine Prodrug 109 Sublingual Film (AQST-109) in Healthy Male Volunteers.”
Andrew Winslow, MD, allergy/immunology fellow, University of North Carolina.
Marcus Shaker, MD, pediatric allergist, Dartmouth Geisel School of Medicine.
ARS Pharmaceuticals, San Diego, CA.
Bryn Pharma, Raleigh, North Carolina.
Aquestive Therapeutics, Warren, NJ.
Brian Schroer, MD, director of allergy and immunology, Akron Children’s Hospital, Akron, OH.
Richard Lowenthal, co-founder, CEO, ARS Pharmaceuticals.
David Stukus, MD, professor of clinical pediatrics, Nationwide Children’s Hospital, Columbus, OH.
